Calendar of Events
Tuesday, July 25
Source: crossville-chronicle.com
Stay updated with breaking news from Bleeding Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Efaconescotog alfa defined a new therapy class by the US Food and Drug Administration (FDA) as the first and best-in-class high-sustained FVIII therapy.
Efanesoctocog alfa demonstrates promising results in new phase 3 data emphasizing the drug's potential to address unmet needs within the hemophilia community.